Trials / Recruiting
RecruitingNCT04803955
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients: a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 424 (estimated)
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study of Kukoamine B Mesilate in Sepsis Patients
Detailed description
To Assess Efficacy,Safety,Pharmacokinetics of Kukoamine B Mesilate in Sepsis Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 16mg，KB | 16mg,Q8h±3min,Day1-Day7 |
| DRUG | Placebos | 16mg,Q8h±3min,Day1-Day7 |
Timeline
- Start date
- 2021-05-15
- Primary completion
- 2024-05-30
- Completion
- 2024-06-30
- First posted
- 2021-03-18
- Last updated
- 2024-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04803955. Inclusion in this directory is not an endorsement.